• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

ZNF169 Drives Thyroid Cancer Progression by Activating Downstream Effector FBXW10

by
November 11, 2026
in Biology
Reading Time: 6 mins read
0
ZNF169 Drives Thyroid Cancer Progression by Activating Downstream Effector FBXW10

ZNF169 Drives Thyroid Cancer Progression by Activating Downstream Effector FBXW10

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Investigators examining thyroid carcinoma have identified zinc finger protein 169, known as ZNF169, as an oncogenic transcription regulator that accelerates tumor progression by stimulating F-box and WD repeat domain-containing protein 10, or FBXW10. Publishing in the journal Cell Division, the research team detailed how elevated ZNF169 stimulates malignant proliferation, enhances transwell migration, suppresses apoptosis, and expedites cell cycle progression across human thyroid carcinoma lines. Using clinical surgical specimens alongside matched adjacent non-cancerous tissues, the authors established that this regulatory axis is markedly upregulated in patient tumors relative to healthy thyroid epithelium. In vitro genetic manipulations and in vivo murine xenograft models corroborated that knocking down ZNF169 impairs tumor growth, whereas ectopic overexpression promotes neoplastic expansion. Crucially, silencing FBXW10 reversed the proliferative advantages conferred by elevated ZNF169, establishing that FBXW10 serves as a pivotal downstream effector facilitating thyroid cancer advancement.

Thyroid cancer originates within thyroid follicular cells and represents the most common endocrine malignancy worldwide. Over recent decades, clinical surveillance data have documented a steady rise in thyroid carcinoma incidence, including a 211 percent increase in the United States between 1975 and 2013. More than 95 percent of thyroid neoplasms are indolent tumors effectively resolved through surgical resection combined with radioactive iodine ablation. Consequently, five-year survival rates for well-differentiated thyroid carcinoma reach approximately 93 percent in women and 88 percent in men. Nevertheless, a distinct subset of patients present with aggressive, advanced-stage disease exhibiting dedifferentiation or therapeutic resistance. While select patients benefit from targeted therapies or immunotherapies, numbers of advanced cases face no effective therapeutic options, creating an urgent clinical imperative to identify novel oncogenic mechanisms and pinpoint new molecular vulnerabilities.

Pathologically, thyroid carcinoma encompasses diverse variants including papillary thyroid carcinoma, follicular thyroid carcinoma, Hürthle cell carcinoma, medullary thyroid carcinoma, and anaplastic thyroid carcinoma, each characterized by distinct mutations governing cellular proliferation. In papillary tumors, BRAF point mutations and RET/PTC rearrangements predominate, accounting for 40 to 60 percent and 20 percent of cases, respectively. Follicular malignancies frequently harbor KRAS mutations in 45 percent of cases or PAX-8/PPARγ rearrangements in 35 percent, activating downstream MAPK and PI3K cascades, alongside mutations in PTEN and PI3KCA that each appear in approximately 10 percent of cases. Anaplastic tumors commonly accumulate alterations in TP53 and β-catenin. Against this heterogeneous landscape, the researchers examined ZNF169, a 603-amino-acid nuclear transcription factor on chromosome 9q22 containing one Krüppel-associated box domain and 13 C2H2-type zinc fingers, alongside FBXW10 on chromosome 17p12, an F-box ubiquitin ligase family member linked to renal and liver cancers.

To evaluate clinical relevance, the investigators examined surgical tissue specimens from 25 patients diagnosed with thyroid carcinoma at Hunan Cancer Hospital in Changsha, China, enrolled between May 2017 and October 2017. The patient cohort comprised 18 women and seven men, with a median age of 44 years ranging between 26 and 66 years, each evaluated alongside matched adjacent non-cancerous thyroid tissue. Immunohistochemical staining using an anti-ZNF169 antibody scored across four tiers revealed that ZNF169 protein was highly expressed in thyroid carcinoma tissues compared to healthy controls. Quantitative reverse transcription PCR and western blot assays subsequently evaluated baseline expression across established human thyroid carcinoma cell lines, including TPC1 papillary cells, BCPAP poorly differentiated cells, and K1 carcinoma cells. All three malignant cultures demonstrated significantly higher ZNF169 messenger RNA and protein levels compared to Nthy-ori 3-1, a normal human primary thyroid follicular epithelial cell line.

Having observed baseline overexpression in clinical specimens and cell lines, the team examined the functional consequences of suppressing ZNF169 using short hairpin RNA sequences delivered via pcDNA3.1 vectors into TPC1 and BCPAP cells. Western blotting and quantitative PCR confirmed knockdown efficiency following transfection with two constructs, designated shZNF169#1 and shZNF169#2, normalized against beta-actin and GAPDH controls. Cell Counting Kit-8 colorimetric assays revealed that ZNF169 knockdown markedly suppressed cellular proliferation over 24, 48, and 72 hours relative to negative control vectors. Furthermore, colony formation assays maintained across 14 days and stained with Giemsa showed that shRNA-treated cells formed significantly fewer colonies containing over 50 cells. In transwell migration chambers using 10 percent fetal bovine serum as a chemoattractant, silencing ZNF169 markedly impaired migration, accompanied by upregulation of p21 and E-cadherin alongside downregulation of mesenchymal markers N-cadherin and Vimentin.

To evaluate whether elevated ZNF169 actively potentiates malignancy, the authors engineered an overexpression plasmid utilizing the pCDH-CMV vector and transfected it into K1 thyroid carcinoma cells. Ectopic ZNF169 expression yielded substantial increases in cell viability, while 14-day colony formation assays demonstrated an approximate 50 percent increase in colony numbers compared to empty vector controls. Transwell assays similarly showed a three-fold expansion in migratory capacity following ZNF169 overexpression, accompanied by decreased p21 and E-cadherin levels together with heightened N-cadherin and Vimentin abundance. Flow cytometry employing Annexin V-FITC and propidium iodide staining established that ZNF169 knockdown induced apoptosis in BCPAP and TPC1 cells, whereas ZNF169 overexpression inhibited apoptosis in K1 cells. Furthermore, cell cycle analysis using propidium iodide staining demonstrated that silencing ZNF169 arrested cells in G0/G1 phase while reducing S phase proportions, whereas overexpressing ZNF169 promoted cell cycle progression with increased S stage cells.

Seeking the downstream molecular mechanism through which ZNF169 coordinates these aggressive traits, the researchers interrogated the starBase V3.0 database across 510 clinical thyroid carcinoma datasets, uncovering a statistically significant positive expression correlation between ZNF169 and FBXW10. Laboratory validation confirmed this computational correlation, as silencing ZNF169 consistently reduced FBXW10 messenger RNA and protein in TPC1 and BCPAP cells, whereas ZNF169 overexpression elevated FBXW10 expression in K1 cells. To establish whether ZNF169 directly governs FBXW10 transcription, the researchers constructed dual-luciferase reporter vectors using the psiCheck 2 backbone containing the FBXW10 promoter sequence between Renilla and firefly luciferase genes. Luciferase reporter activity normalized to Renilla was markedly suppressed following ZNF169 silencing in TPC1 and BCPAP cells, but enhanced following ZNF169 overexpression in K1 cells. Subsequent chromatin immunoprecipitation followed by quantitative PCR and agarose gel electrophoresis confirmed substantial enrichment of the FBXW10 promoter in cross-linked K1 lysates pulled down by anti-ZNF169 antibodies.

Given prior evidence establishing that FBXW10 operates as an oncogene in clear cell renal cell carcinoma and hepatocellular carcinoma, the team investigated its independent contribution to thyroid carcinoma pathophysiology. Using two targeted short hairpin RNA sequences designated shFBXW10#1 and shFBXW10#2, the investigators silenced FBXW10 in TPC1 and BCPAP cells, confirming knockdown efficiency through quantitative PCR and western blot analysis. Cell Counting Kit-8 viability assays indicated that depletion of FBXW10 produced an approximate 50 percent decrease in TPC1 cell viability across culture intervals compared to control transfection groups. Correspondingly, colony formation experiments demonstrated an approximate 50 percent reduction in macroscopic colony numbers following FBXW10 suppression in TPC1 cells, with parallel anti-proliferative effects replicated in BCPAP cultures. These empirical measurements verified that FBXW10 possesses autonomous oncogenic properties within thyroid carcinoma cells, confirming that its transcriptional stimulation by upstream nuclear factors constitutes a critical pathway fueling thyroid tumor cell proliferation.

To verify whether FBXW10 represents the indispensable downstream mediator of ZNF169-driven oncogenesis, the researchers executed simultaneous knockdown and overexpression recovery experiments in cultured cells and nude mouse xenografts. In TPC1 cells depleted of ZNF169, transfection of an FBXW10 overexpression plasmid restored suppressed viability and rescued colony formation counts toward control baselines. Conversely, in K1 cells overexpressing ZNF169, introducing shFBXW10 effectively reversed the heightened viability and colony proliferation driven by ZNF169. In vivo validation utilized fifteen four-to-six-week-old BALB/c nude mice assigned into three cohorts of five animals each, receiving subcutaneous flank injections of 10 million K1 cells transfected with control vector, ZNF169 overexpression plasmid, or ZNF169 combined with shFBXW10. At necropsy on day 25 post-injection, xenograft tumor dimensions, volumes, and excised tumor weights from the ZNF169 overexpression cohort were significantly elevated compared to controls, whereas tumors from the ZNF169 and shFBXW10 combination group were greatly lower, confirming functional rescue in vivo.

While these findings delineate an oncogenic ZNF169/FBXW10 regulatory axis, the authors underscored notable study limitations that necessitate further mechanistic and translational evaluation. Because ZNF169 operates as a multi-target nuclear transcription factor regulating diverse downstream transcripts, direct therapeutic inhibition of ZNF169 could induce extensive side effects in healthy organs such as the kidneys, liver, spleen, and heart where it normally resides; therefore, selectively targeting the downstream ubiquitin ligase FBXW10 may represent a safer clinical strategy. Additionally, the precise nucleotide binding motifs recognized by ZNF169 within the FBXW10 promoter remain to be mapped, and potential transcriptional co-factors or co-enhancers—analogous to PCBD2 cooperating with HNF1β or CDK5RAP3 enhancing STAT3 activity—warrant deeper identification. Furthermore, future investigations must examine FBXW10 promoter methylation dynamics, evaluate tumor microenvironment interactions using immunocompetent animal models rather than immunodeficient nude mice, and define how ZNF169 activity stratifies across distinct thyroid cancer histological variants including papillary, follicular, medullary, and anaplastic carcinomas.

Subject of Research: Molecular mechanisms of ZNF169 and FBXW10 in thyroid carcinoma progression

Article Title: ZNF169 promotes thyroid cancer progression via upregulating FBXW10

Article References: Luo, W., Xiao, Q., & Fu, Y. (2025). ZNF169 promotes thyroid cancer progression via upregulating FBXW10. Cell Division, 20(1), Article 3. https://doi.org/10.1186/s13008-024-00139-5

Image Credits: AI Generated

DOI: 10.1186/s13008-024-00139-5

Keywords: thyroid carcinoma, ZNF169, FBXW10, transcription factor, cell proliferation, tumorigenesis, cell migration, apoptosis, cell cycle progression, chromatin immunoprecipitation, luciferase reporter assay, TPC1 cells, BCPAP cells, K1 cells, nude mouse xenograft, p21, epithelial-mesenchymal transition, oncogene

News Source: Nathaniel Bowman. (November 11, 2026). ZNF169 Drives Thyroid Cancer Progression by Activating Downstream Effector FBXW10. Scienmag.

Tags: ApoptosisBCPAP cellsCell cycle progressioncell migrationCell proliferationchromatin immunoprecipitationEpithelial-mesenchymal transitionFBXW10K1 cellsLuciferase Reporter Assaynude mouse xenograftoncogenep21thyroid carcinomaTPC1 cellstranscription factortumorigenesisZNF169
Share12Tweet7Share2ShareShareShare1

Related Posts

Review Synthesizes Localization Microscopy Advances for Resolving Dynamic Chromatin Architecture

Review Synthesizes Localization Microscopy Advances for Resolving Dynamic Chromatin Architecture

November 16, 2026
Melatonin Application Increases Rice Yield Under Salt Stress by 20 Percent

Melatonin Application Increases Rice Yield Under Salt Stress by 20 Percent

November 16, 2026

Legal Scholars Propose Strange Loop Ethics to Prevent Environmental Problem Shifting

November 16, 2026

Tracking Seven Decades of Genotoxicity Research in India

November 16, 2026

POPULAR NEWS

  • Human Amniotic Tissues Express HER3 and Transport Cancer-Targeted Nanobioparticles

    Human Amniotic Tissues Express HER3 and Transport Cancer-Targeted Nanobioparticles

    29 shares
    Share 12 Tweet 7
  • Intravenous Morphine Provides Brief Pain Relief While Low-Dose Butorphanol Fails in Cattle

    29 shares
    Share 12 Tweet 7
  • Korean Cohort Study Links Urate Transporter Variants to Elevated Hyperuricemia Risk

    29 shares
    Share 12 Tweet 7
  • SENEX Expression Promotes Apoptosis Resistance and Invasive Growth in Burkitt Lymphoma

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Excessive Greenhouse Nitrogen Fertilization Reduces Zucchini Yield While Multiplying Environmental Losses

Adaptive Topology Strategy Accurately Identifies Fault Action Zones in Distribution Networks

Epigenetic Regulator PHF8 Drives Cancer Progression and Presents New Therapeutic Target

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 87 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.